4 Tetraphase Pharmaceuticals Analyst Ratings, Earnings, Dividends and Insider Trades | $TTPH | NASDAQ:TTPH | Analyst Ratings Network Follow @RatingsNetwork Find a Company: Login Stock Ratings Today's Ratings U.S. Analyst Ratings (NYSE and NASDAQ) All U.S. Ratings Upgrades Downgrades New Coverage Price Target Changes Rating Reiterations Canadian Analyst Ratings (TSE and TSV) U.K. Analyst Ratings (LSE) Australian Analyst Ratings (ASX) Lookup Company Ratings Free Ratings Newsletter ARN Daily Premium ($) RatingsDB ($) Stock Ratings App Earnings Today's Announcements Tomorrow's Announcements Free Earnings Newsletter CER Wire Premium ($) Lookup Company Earnings Dividends Insider Trades About Contact Tetraphase Pharmaceuticals Company Profile (NASDAQ:TTPH) Tweet Analyst RatingsEarningsDividendsInsider TradesCompany ProfileSocial ActivityToday's Chart Consensus Ratings for Tetraphase Pharmaceuticals (NASDAQ:TTPH) (?) The ratings breakdown includes the most recent rating from each analyst that has rated the stock within the last twelve months. The ratings score is a calculation of the average number of sell, hold, buy and strong buy ratings (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). The consensus price target is a mean average of the most recent price target set by each analyst that has set a price target for the stock in the last twelve months.Ratings Breakdown: 1 Hold Rating(s), 7 Buy Rating(s)Consensus Rating:Buy (Score: 2.88)Consensus Price Target: $17.67 (44.10% upside) Analysts' Ratings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH) Show: All Ratings For This Stock Only the Most Recent Rating From Each Brokerage DateFirmActionRatingPrice TargetDetailsShare3/6/2014Needham & CompanyBoost Price TargetBuy$15.00 -> $17.00View 1/10/2014BarclaysBoost Price TargetOverweight$16.00 -> $17.00View 11/13/2013GuggenheimInitiated CoverageBuy$25.00View 10/2/2013Ladenburg ThalmannBoost Price TargetBuy$13.00 -> $15.00View 10/1/2013JMP SecuritiesBoost Price TargetMarket Outperform$12.00 -> $16.00View 10/1/2013Needham & CompanyReiterated RatingBuy$12.00 -> $15.00View 9/30/2013WBB SecuritiesInitiated CoverageSpeculative BuyView 8/21/2013Ladenburg ThalmannInitiated CoverageBuy$13.00View 4/15/2013JMP SecuritiesInitiated CoverageOutperform$12.00View 4/15/2013BMO Capital MarketsInitiated CoverageOutperformView 4/15/2013Stifel NicolausInitiated CoverageBuy$16.00View 4/15/2013BarclaysInitiated CoverageOverweight$16.00 -> $16.00View 4/15/2013Needham & CompanyInitiated CoverageBuy$12.00View (Data available from 3/7/2012 forward) Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetailsShare3/6/2014($0.46)($0.49)ViewN/AView 11/11/2013Q3($0.39)($0.49)$2.43 million$2.20 millionViewN/AView 5/13/2013Q113($0.27)($0.30)$2.49 million$2.70 millionViewN/AView (Data available from 1/1/2011 forward) Dividend History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)No dividend announcements for this company have been tracked by Analyst Ratings Network Insider Trading History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionSEC LinkShare2/20/2014Joyce SutcliffeSVPSell11,494$14.00$160,916.00View 2/12/2014David Charles LubnerCFOSell4,506$13.92$62,723.52View 2/7/2014David Charles LubnerCFOSell9,928$14.22$141,176.16View 2/5/2014Joyce SutcliffeSVPSell11,494$13.93$160,111.42View 9/18/2013Ventures Vi Lp Cmeamajor shareholderSell100,000$10.20$1,020,000.00View 9/17/2013Ventures Vi Lp Cmeamajor shareholderSell53,468$9.26$495,113.68View 3/25/2013John Gordon FreundDirectorBuy681,012$7.00$4,767,084.00View 3/25/2013Medical Fund Lp ExcelMajor ShareholderBuy496,121$7.00$3,472,847.00View 3/20/2013Fmr LlcInsiderBuy642,857$7.00$4,499,999.00View (Data available from 1/1/2013 forward) About Tetraphase Pharmaceuticals Tetraphase Pharmaceuticals, Inc., incorporated on July 7, 2006, is a clinical stage biopharmaceutical company. The Company's product candidate, eravacycline, is a fully synthetic tetracycline derivative that the Company is developing as a broad-spectrum intravenous and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multi-drug resistant infections, including multi-drug resistant Gram-negative infections. . The Company's frequently used products, such as Zyvox and Cubicin, are limited to Gram-positive bacteria and thus are rarely used as a first-line empiric monotherapy if broad bacterial coverage is required. During the year ended December 31, 2012, completed a Phase 2 clinical trial of eravacycline with intravenous administration for the treatment of patients with complicated intra-abdominal infections, or cIAI, and are finalizing its pivotal Phase 3 program for eravacycline. Headlines: (3/6) Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results (3/4) Tetraphase Pharmaceuticals to Present at Upcoming Investor Conferences (3/6) Tetraphase Pharmaceuticals reports net loss of $11.3 million for Q4 2013 (3/4) Press Release Industry, Sector and Symbol: Sector: N/A Industry: N/A Sub-Industry: N/A Exchange: NASDAQ Symbol: TTPH CUSIP: Key Metrics: Previous Close: $13.4550 Day Moving Average: $14.5882200 Day Moving Average: $12.3883 P/E Ratio: N/AP/E Growth: N/AMarket Cap: $308.7MCurrent Quarter EPS Consensus Estimate: $-1.92 EPS Additional Links: View TTPH on Google FinanceView TTPH on Yahoo FinanceView TTPH's Company Profile on ReutersSearch for Tetraphase Pharmaceuticals Inc on Google Tetraphase Pharmaceuticals (NASDAQ:TTPH) Chart for Friday, March, 7, 2014 (Chart Provided by Yahoo Finance) © Analyst Ratings Network 2010-2014. All rights reserved. Contact | Terms and Conditions | Subscribe | Subscribe Earnings | Google+ Analyst Ratings Network does not provide financial advice and does not issue recommendations or offers to buy or sell any security. Learn more.